by MASA | Dec 15, 2024 | Uncategorized
FDA approved Epinephrine nasal spray (neffy) for emergency treatment of allergic reaction type 1 in August in adults and pediatric patients who weigh at least 30 kg (or around 66 lbs). Neffy provides an option to treat anaphylaxis that does not involve injection,...
by MASA | Oct 2, 2024 | Asthma, Clinical Research
Are you or your child diagnosed with Asthma for at least 1 year and between the ages of 12-17? You may be eligible for a study and receive compensation for time and travel >> SIGN UP HERE << or contact us and our research coordinator will be in touch for...
by MASA | Aug 15, 2024 | Drug Updates, Rare Diseases
What is D.R.E.S.S.? Drug Reaction with Eosinophilia and Systemic Symptoms (D.R.E.S.S.) is a type of drug allergy which can occur as a reaction to a large variety of medications. Symptoms include fever, rash, facial swelling, enlarged lymph nodes and kidney or liver...
by MASA | Aug 8, 2024 | Celiac Disease
In this 2-minute radio interview, Dr. Siri explains the difference between Celiac Disease and Gluten intolerance and announces the clinical study for a celiac new treatment in the SWIA research center in Normal, IL. Have a listen and share! Text transcription:...
by MASA | Jul 31, 2024 | Drug Updates
The FDA approved Zoryve cream (0.15%) for mild to moderate atopic dermatitis this year for adults and children aged above 6 years old. Roflumilast cream (marketed under the name Zoryve) is a non-steroidal topical cream that is applied once daily to affected areas of...
